Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome

NCT05307328 is registered in ClinicalTrials.gov with Sparrow Pharmaceuticals as lead sponsor.

NCT NCT05307328
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05307328 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome
Lead sponsor
Sparrow Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
September 1, 2022
Completion date
August 1, 2025
Enrollment
26 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

cortisol excess, cortisol overproduction, cortisol; hypersecretion, cushing disease due to increased acth secretion, cushing's syndrome i, ectopic acth secretion